News

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.

SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.

Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema

The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

A new functional classification can help achieve precise vision goals

With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Johann Krüger, MD, shares insights from 26 years of experience

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

The framework covers ocular hypertension to severe progression

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada

Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects